PT1581812E - Composições e métodos para diagnóstico e tratamento de cancros do cólon - Google Patents

Composições e métodos para diagnóstico e tratamento de cancros do cólon Download PDF

Info

Publication number
PT1581812E
PT1581812E PT04700319T PT04700319T PT1581812E PT 1581812 E PT1581812 E PT 1581812E PT 04700319 T PT04700319 T PT 04700319T PT 04700319 T PT04700319 T PT 04700319T PT 1581812 E PT1581812 E PT 1581812E
Authority
PT
Portugal
Prior art keywords
colon cancer
diagnosing
compositions
methods
colon cancers
Prior art date
Application number
PT04700319T
Other languages
English (en)
Inventor
Wei Liu
Robert Vincent Martinez
Eugene Brown
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PT1581812E publication Critical patent/PT1581812E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/0061—The surface being organic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
    • B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00709—Type of synthesis
    • B01J2219/00711—Light-directed synthesis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Food Science & Technology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
PT04700319T 2003-01-06 2004-01-06 Composições e métodos para diagnóstico e tratamento de cancros do cólon PT1581812E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43800003P 2003-01-06 2003-01-06

Publications (1)

Publication Number Publication Date
PT1581812E true PT1581812E (pt) 2008-09-22

Family

ID=32713264

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04700319T PT1581812E (pt) 2003-01-06 2004-01-06 Composições e métodos para diagnóstico e tratamento de cancros do cólon

Country Status (11)

Country Link
US (1) US20040265230A1 (pt)
EP (2) EP1998177A3 (pt)
AT (1) ATE401575T1 (pt)
AU (1) AU2004203749A1 (pt)
CA (1) CA2511907A1 (pt)
DE (1) DE602004015064D1 (pt)
DK (1) DK1581812T3 (pt)
ES (1) ES2309485T3 (pt)
PT (1) PT1581812E (pt)
SI (1) SI1581812T1 (pt)
WO (1) WO2004061423A2 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DE10339820A1 (de) * 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
US7872117B2 (en) * 2004-03-26 2011-01-18 Van Andel Research Institute c-met siRNA adenovirus vectors inhibit cancer cell growth, invasion and tumorigenicity
WO2006088483A2 (en) * 2004-06-16 2006-08-24 Trustees Of Dartmouth College Compositions and methods for inhibiting the synthesis or expression of mmp-1
EP1786906A2 (en) * 2004-09-09 2007-05-23 Exonhit Therapeutics SA Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
US20100041167A1 (en) * 2004-12-16 2010-02-18 Perseus Proteomics Inc. Drug for diagnosing large intestinal cancer and/or polyp, observing postoperative course and monitoring recurrence
US20090305963A1 (en) * 2005-01-19 2009-12-10 Sukhatme Vikas P Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
BRPI0607676A2 (pt) * 2005-04-27 2009-09-22 Univ Indiana Res & Tech Corp anticorpos contra isoformas de cspcna e usos destes
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
DK1910839T3 (en) * 2005-07-27 2016-07-04 Oncotherapy Science Inc Gene TOM34 associated with colon cancer
US20090317392A1 (en) * 2005-07-27 2009-12-24 Yusuke Nakamura Method of diagnosing small cell lung cancer
US20090005307A1 (en) * 2005-09-21 2009-01-01 Burnham Institute For Medical Research Compositions and Methods for Detection of Colorectal Cancer
CA2624221A1 (en) * 2005-10-24 2007-05-03 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US20070122854A1 (en) * 2005-11-29 2007-05-31 Rnl Bio Co. Ltd. Method for diagnosing colon cancer
US20080241110A1 (en) * 2005-11-29 2008-10-02 Nevada Cancer Institute Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
US7790407B2 (en) * 2005-11-29 2010-09-07 Nevada Cancer Institute Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
US7687062B2 (en) * 2005-11-29 2010-03-30 Rnl Bio Co. Ltd. Method for diagnosing colon cancer
US9095549B2 (en) * 2005-12-16 2015-08-04 Electrophoretics Limited Diagnosis and prognosis of colorectal cancer
US8258287B2 (en) * 2005-12-21 2012-09-04 Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) Interfering RNAs targeting the morbillivirus nucleoprotein gene
ES2277785B1 (es) * 2005-12-21 2008-06-16 Oryzon Genomics, S.A. Metodo de analisis de expresion diferencial en cancer colorectal.
EP1884569A1 (en) 2006-07-31 2008-02-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sensitization of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
WO2008020653A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Use of holliday junction-recognizing protein related to cancer
EP2468887A1 (en) * 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
JP2010517941A (ja) * 2007-01-16 2010-05-27 ザ バーナム インスティテュート フォー メディカル リサーチ 結腸直腸癌の治療のための組成物および方法
US20080299077A1 (en) * 2007-06-01 2008-12-04 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2008151021A1 (en) * 2007-06-01 2008-12-11 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
EP2638917A1 (en) * 2007-06-29 2013-09-18 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Method of fixing and expressing physiologically active substance
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
AU2014201635B2 (en) * 2007-07-15 2016-06-23 Technion Research & Development Foundation Ltd. Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
UA103882C2 (uk) * 2007-07-27 2013-12-10 Імматікс Біотекнолоджіс Гмбх Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
SI2182981T1 (sl) 2007-08-02 2013-05-31 Gilead Biologics, Inc. Postopki in sestavki za zdravljenje in diagnozo fibroze
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
EP2185937B2 (en) * 2007-09-07 2014-07-16 Universität Zürich Method for assaying sepsis in humans
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
US20090233294A1 (en) * 2008-01-29 2009-09-17 Elias Georges Uhrf1 directed diagnostics for neoplastic disease
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
KR100958086B1 (ko) 2009-07-28 2010-05-14 한국생명공학연구원 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101007574B1 (ko) 2009-07-28 2011-01-14 한국생명공학연구원 대장암 과발현 유전자를 이용한 대장암 진단 마커
EP2467393A4 (en) * 2009-08-19 2013-01-23 Blood Systems Inc NEW SPECIES OF ASTROVIRUS
CN102712683B (zh) 2009-08-21 2014-09-10 吉联亚生物科技有限公司 赖氨酰氧化酶和loxl2的催化结构域
US20130023578A1 (en) * 2009-12-31 2013-01-24 Samyang Biopharmaceuticals Corporation siRNA for inhibition of c-Met expression and anticancer composition containing the same
CN105622757A (zh) 2010-02-04 2016-06-01 吉联亚生物科技有限公司 结合赖氨酰氧化酶样2（loxl2）的抗体和其使用方法
WO2011150976A1 (en) 2010-06-04 2011-12-08 bioMérieux Method and kit for the prognosis of colorectal cancer
SG10201509823WA (en) 2010-12-02 2015-12-30 Oncotherapy Science Inc TOMM34 Peptides And Vaccines Including The Same
EP2655661B1 (en) * 2010-12-23 2015-03-11 Agendia N.V. Methods and means for molecular classification of colorectal cancers
US9359605B2 (en) * 2011-03-11 2016-06-07 Sarissa Inc. Method of treating cancer by inhibition of DNA repair proteins
WO2012129758A1 (en) * 2011-03-25 2012-10-04 Biomerieux Method and kit for determining in vitro probability for individual to suffer from colorectal cancer
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
SG11201400499PA (en) 2011-09-20 2014-06-27 Brigham & Womens Hospital Sall4 and uses thereof
GB201207998D0 (en) * 2012-05-08 2012-06-20 Univ Cardiff A screening method for the detection of clostridium difficle
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US20150337318A1 (en) * 2013-01-11 2015-11-26 Phaserx Inc. Rna targeted to c-met
US9862943B1 (en) 2013-06-27 2018-01-09 California Institute Of Technology Long noncoding RNAs and cell reprogramming and differentiation
WO2015057727A1 (en) * 2013-10-14 2015-04-23 Isis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015066212A2 (en) * 2013-10-31 2015-05-07 University Of Hawaii Calpain inhibitors for treatment of inflammatory bowel disease and colorectal cancer
WO2016083624A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for inhibiting the expression of edn1
HUE056607T2 (hu) 2014-12-23 2022-02-28 Immatics Biotechnologies Gmbh Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
PT109454A (pt) * 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda Ácidos nucleicos de interferência e composições que os compreendem
EP3388520A1 (en) * 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
WO2018224731A1 (en) * 2017-06-05 2018-12-13 Ls Cancerdiag Oy A method for determining whether a subject is at risk to develop cancer and tools related thereto
WO2019140088A1 (en) * 2018-01-12 2019-07-18 Celgene Corporation Methods for screening cereblon modifying compounds
US20240141340A1 (en) * 2021-03-05 2024-05-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for use in the treatment of corneal dystrophies

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JP2547714B2 (ja) * 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4798885A (en) * 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
ZA874681B (en) * 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4980281A (en) 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5688655A (en) 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
KR920007887B1 (ko) * 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9509757D0 (en) * 1995-05-13 1995-07-05 Ilford Ltd Toning of photographic print material
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US5965403A (en) * 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999048921A1 (en) * 1998-03-26 1999-09-30 The Board Of Trustees Of The Leland Stanford Junior University Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions
WO2001059109A1 (en) * 2000-02-08 2001-08-16 Millennium Pharmaceuticals, Inc. 39406 protein, a seven transmembrane protein
US20030027323A1 (en) * 2000-09-27 2003-02-06 Feder John N. Novel human G-protein coupled receptor, HGPRBMY5, expressed highly in brain and ovarian tissues
WO2002059376A1 (en) * 2001-01-23 2002-08-01 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
CA2498264A1 (en) * 2002-09-09 2004-05-13 Nura, Inc. G protein coupled receptors and uses thereof
US20060111314A1 (en) * 2002-09-30 2006-05-25 Oncotheraphy Science, Inc. Method for treating or preventing metastasis of colorectal cancers

Also Published As

Publication number Publication date
EP1998177A3 (en) 2009-02-18
SI1581812T1 (sl) 2008-10-31
AU2004203749A1 (en) 2004-07-22
EP1581812A2 (en) 2005-10-05
WO2004061423A2 (en) 2004-07-22
EP1998177A2 (en) 2008-12-03
WO2004061423A3 (en) 2004-12-16
US20040265230A1 (en) 2004-12-30
CA2511907A1 (en) 2004-07-22
DE602004015064D1 (de) 2008-08-28
ATE401575T1 (de) 2008-08-15
ES2309485T3 (es) 2008-12-16
EP1581812B1 (en) 2008-07-16
DK1581812T3 (da) 2008-10-20

Similar Documents

Publication Publication Date Title
PT1581812E (pt) Composições e métodos para diagnóstico e tratamento de cancros do cólon
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
HK1155671A1 (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
EP2298304A3 (en) Carboline derivatives useful in the treatment of cancer
EP1567674A4 (en) AIM FOR THE THERAPY OF COGNITIVE IMMUNITY
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
EP1365034A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
EP1522594A3 (en) Methods and kits for investigating cancer
IL173352A0 (en) Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
WO2005085861A3 (en) Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
ZA200500908B (en) Ruthenium anticancer complexes
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2004029287A3 (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung
NO20055650L (no) Ruteinum (II)-komplekser for behandling av tumorer
HK1066032A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
WO2007035734A3 (en) Cytotoxin compounds and methods of isolation
WO2005082353A3 (en) Use of beta-lapachone for treating or preventing cancer